Use of combination vaccines is associated with improved coverage rates
- PMID: 17529866
- DOI: 10.1097/INF.0b013e31805d7f17
Use of combination vaccines is associated with improved coverage rates
Abstract
Background: The number of shots represented by the routine childhood immunization schedule poses a logistical challenge for providers and a potential deterrent for parents. By reducing the number of injections, use of combination vaccines could lead to fewer deferred doses and improved coverage rates.
Objective: To determine the effect of combination vaccines on coverage rates.
Methods: This was a retrospective study of administrative claims data from the Georgia Department of Community Health Medicaid program conducted from January through September of 2003. Coverage rates were compared between children who received at least 1 dose of HepB/Hib (COMVAX) or DTaP/HepB/IPV (PEDIARIX) (the combination cohort) and children who received no doses of either combination (the reference cohort). Infants with fewer than 4 vaccination visits were excluded from the analysis. Multivariate logistic regression was performed on the whole study population to assess the effect of combination vaccines while controlling for potential confounders. Hepatitis B and pneumococcal conjugate vaccine coverage rates were not included as outcomes.
Results: The study population consisted of 18,821 infants, 16,007 in the combination cohort and 2814 in the reference cohort. Unadjusted coverage rates for DTaP, IPV and the 4 DTaP:3 IPV:1 MMR, 4 DTaP: 3 IPV: 1 MMR: 3 Hib: 1 varicella, and 3 DTaP:3 IPV: 3 Hib series were higher in the combination cohort. Receipt of at least 1 dose of a combination vaccine was independently associated with increased coverage for each of these vaccines and vaccine series when controlling for gender, birth quarter, race, rural versus urban residence and historical provider immunization quality.
Conclusions: Use of combination vaccines in this Medicaid population was associated with improved coverage rates. Additional studies are warranted, including those examining private sector populations and outcomes such as timeliness and cost.
Similar articles
-
Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.Pediatr Infect Dis J. 2009 Feb;28(2):98-101. doi: 10.1097/INF.0b013e318187d047. Pediatr Infect Dis J. 2009. PMID: 19148039
-
Combination vaccine use and vaccination quality in a managed care population.Am J Manag Care. 2007 Sep;13(9):506-12. Am J Manag Care. 2007. PMID: 17803364
-
Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.J Pediatr. 2007 Jul;151(1):43-9, 49.e1-2. doi: 10.1016/j.jpeds.2007.02.013. J Pediatr. 2007. PMID: 17586189 Clinical Trial.
-
Pediatric combined formulation DTaP-IPV/Hib vaccine.Expert Rev Vaccines. 2009 Jul;8(7):831-40. doi: 10.1586/erv.09.59. Expert Rev Vaccines. 2009. PMID: 19538110 Review.
-
Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. Pediatr Infect Dis J. 2009. PMID: 19325452 Review.
Cited by
-
Introduction of a hexavalent vaccine containing acellular pertussis into the national immunization program for infants in Peru: a cost-consequence analysis of vaccination coverage.BMC Health Serv Res. 2024 Oct 10;24(1):1216. doi: 10.1186/s12913-024-11684-8. BMC Health Serv Res. 2024. PMID: 39390544 Free PMC article.
-
A prospective, observational, multi-center, post-marketing safety surveillance study of the GSK combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b invasive infections (DTaP-IPV/Hib) in South Korean infants.Hum Vaccin Immunother. 2024 Dec 31;20(1):2406060. doi: 10.1080/21645515.2024.2406060. Epub 2024 Oct 8. Hum Vaccin Immunother. 2024. PMID: 39376187 Free PMC article.
-
Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus.Front Immunol. 2024 Jun 21;15:1376395. doi: 10.3389/fimmu.2024.1376395. eCollection 2024. Front Immunol. 2024. PMID: 38975350 Free PMC article.
-
Shaping immunity against infectious diseases with multivalent DNA vaccines.Vaccine Insights. 2024 Apr;3(2):29-33. doi: 10.18609/vac.2024.002. Epub 2024 Feb 15. Vaccine Insights. 2024. PMID: 38694840 Free PMC article.
-
Co-Administration of Influenza and COVID-19 Vaccines: Policy Review and Vaccination Coverage Trends in the European Union, UK, US, and Canada between 2019 and 2023.Vaccines (Basel). 2024 Feb 19;12(2):216. doi: 10.3390/vaccines12020216. Vaccines (Basel). 2024. PMID: 38400199 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources

